DOCSLIB.ORG

Vaccine Efficacy Against Primary and Metastatic Cancer with in Vitro-­Generated CD103+ Conventional Dendritic Cells

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Vaccine Efficacy Against Primary and Metastatic Cancer with in Vitro-­Generated CD103+ Conventional Dendritic Cells Open access Original research J Immunother Cancer: first published as 10.1136/jitc-2019-000474 on 8 April 2020. Downloaded from Vaccine efficacy against primary and metastatic cancer with in vitro- generated CD103+ conventional dendritic cells Yifan Zhou, Natalie Slone, Taylor T Chrisikos, Oleksandr Kyrysyuk, Rachel L Babcock, Yusra B Medik, Haiyan S Li, Eugenie S Kleinerman, Stephanie S Watowich To cite: Zhou Y, Slone N, ABSTRACT BACKGROUND Chrisikos TT, et al. Vaccine Background Type 1 conventional dendritic cells (cDC1s) T cell-based immunotherapy and antibody- efficacy against primary and possess efficient antigen presentation and cross- mediated immune checkpoint blockade are metastatic cancer with in vitro- presentation activity, as well as potent T cell priming generated CD103+ conventional among the most exciting advances in cancer ability. Tissue- resident cDC1s (CD103+ cDC1s in mice, dendritic cells. Journal for + therapy over the past decade, eliciting durable ImmunoTherapy of Cancer CD141 cDC1s in humans) are linked with improved tumor control, yet the efficacy of immunotherapy using this control of several cancers and prolonging 2020;8:e000474. doi:10.1136/ survival rates.1 2 Nonetheless, limitations exist jitc-2019-000474 population is understudied. Methods We generated murine CD103+ cDC1s in vitro with current immunotherapies including non- responsiveness or adverse events.3 Thus, ► Additional material is and examined their expression of cDC1- related factors, published online only. To view antigen cross- presentation activity, and accumulation approaches to improve the specificity, effec- please visit the journal online in tumor- draining lymph nodes (TdLNs). The antitumor tiveness, and safety of cancer immunotherapy + (http:// dx. doi. org/ 10. 1136/ jitc- efficacy of the in vitro- generated CD103 cDC1s was across patient populations and cancer types 2019- 000474). studied in murine melanoma and osteosarcoma models. are needed. We evaluated tumor responses on vaccination with Dendritic cells (DCs) are the principal Accepted 21 February 2020 CD103+ cDC1s, compared these to vaccination with + antigen- presenting cells of the immune monocyte- derived DCs (MoDCs), tested CD103 cDC1 system and therefore shape adaptive, anti- vaccination with checkpoint blockade, and examined the 4 antimetastatic activity of CD103+ cDC1s. tumor immunity. These features indicate Results In vitro- generated CD103+ cDC1s produced DCs as a promising tool for anticancer treat- 5–7 cDC1- associated factors such as interleukin- 12p70 ment. The majority of DCs used in clin- http://jitc.bmj.com/ and CXCL10, and demonstrated antigen cross- ical trials have been generated from human presentation activity on stimulation with the toll- like CD14+ monocytes (MoDCs) or CD34+ progen- receptor 3 agonist polyinosinic:polycytidylic acid 8 + itors in culture. While these DCs can be (poly I:C). In vitro- generated CD103 cDC1s also produced in abundance and are capable of migrated to TdLNs following poly I:C treatment and inducing tumor- specific T cells with minimal intratumoral delivery. Vaccination with poly I:C- 7–9 activated and tumor antigen- loaded CD103+ cDC1s side effects, their efficacy remains limited. on September 28, 2021 by guest. Protected copyright. enhanced tumor infiltration of tumor antigen- specific More recently, specific DC populations and interferon-γ+ CD8+ T cells, and suppressed including plasmacytoid DCs (pDCs) and type melanoma and osteosarcoma growth. CD103+ cDC1s 2 conventional DCs (cDC2s) have yielded showed superior antitumor efficacy compared with clinical responses,10 11 yet these subsets are MoDC vaccination, and led to complete regression of relatively sparse in vivo. The efficacy or feasi- 100% of osteosarcoma tumors in combination with bility of current DC vaccines, therefore, may CTLA-4 antibody- mediated checkpoint blockade. In be limited by issues such as use of suboptimal vitro- generated CD103+ cDC1s effectively protected or rare DC subsets. © Author(s) (or their mice from pulmonary melanoma and osteosarcoma employer(s)) 2020. Re- use metastases. Type 1 cDCs (cDC1s) exhibit several permitted under CC BY-NC. No features that predict important roles in acti- commercial re- use. See rights Conclusions Our data indicate an in vitro- generated + and permissions. Published by CD103 cDC1 vaccine elicits systemic and long- vating antitumor immunity, and abundance BMJ. lasting tumor- specificT cell- mediated cytotoxicity, of cDC1s within tumors correlates with Immunology, University of Texas which restrains primary and metastatic tumor growth. improved patient outcomes and response to + MD Anderson Cancer Center, The CD103 cDC1 vaccine was superior to MoDCs immune checkpoint blockade.12 13 The cDC1 Houston, Texas, USA and enhanced response to immune checkpoint subset possesses antigen uptake, antigen blockade. These results indicate the potential for new Correspondence to presentation, and antigen cross-presentation immunotherapies based on use of cDC1s alone or in abilities. Moreover, migratory CD103+ cDC1s Dr Stephanie S Watowich; combination with checkpoint blockade. swatowic@ mdanderson. org transport tissue or tumor antigens to lymph Zhou Y, et al. J Immunother Cancer 2020;8:e000474. doi:10.1136/jitc-2019-000474 1 Open access J Immunother Cancer: first published as 10.1136/jitc-2019-000474 on 8 April 2020. Downloaded from nodes (LNs) and elicit antigen- specific CD8+ T cell METHODS responses.14–18 CD103+ cDC1s can be recruited to tumors CD103+ cDC1 vaccination by T cell- expressed chemokines including XCL1, where In vitro- generated CD103+ cDC1s29 were cultured they participate in further T cell recruitment through (2.5–4.5×106/mL) in Roswell Park Memorial Institute expression of chemoattractants such as CXCL10.12 19 (RPMI) 1640 medium containing 10% heat-inactivated Consistent with these functions, lymphoid organ-resident fetal bovine serum (FBS) (Atlanta Biologicals, Atlanta, CD8α+ cDC1s induced CD8+ T cell responses and protected Georgia, USA), 1% penicillin-streptomycin, 1 mM mice against melanoma engraftment, while treatments sodium pyruvate, and 50 µM β-mercaptoethanol (RPMI to expand and activate locally recruited CD103+ cDC1s 1640 complete medium) ± 20 µg/mL poly I:C (Sigma, St increased the efficacy of B- raf kinase (BRAF) inhibition Louis, Missouri, USA), 5% XG-3 supernatant or 20 ng/ and PD-1 blockade in controlling melanoma.18 20 Collec- mL granulocyte- macrophage colony- stimulating factor tively, these features suggest cDC1-based vaccines will (GM- CSF) and the surrogate tumor antigens ovalbumin elicit antitumor activity, yet this concept requires further (OVA; 100–400 µg/mL) (Sigma) or K7M3 tumor lysate validation. Moreover, whether cDC1- based vaccines for 4 hours. Cells were washed twice with phosphate- 6 protect from metastatic disease is important to examine, buffered saline (PBS) and injected (0.5–3×10 ) into as metastasis is a primary cause of mortality in patients melanoma or osteosarcoma tumors (intratumoral (i.t.)), with cancer. one or two times 4–7 days following tumor implantation, 2 Melanoma and melanoma metastatic disease are respon- when tumor sizes reached 10–20 mm . In bilateral tumor + 2 7 assays, poly I:C- treated and tumor antigen- loaded CD103 sive to immunotherapies such as checkpoint blockade. 6 A number of other tumor types, however, remain poorly cDC1s (2–3×10 cells) were injected into left-side tumors; responsive or refractory. In particular, pediatric solid right- side tumors remained untreated. For metastasis assays, poly I:C- treated and tumor antigen- loaded CD103+ tumors are frequently non-responsive to immunotherapy. 6 Additionally, these tumors often develop resistance to cDC1s (1–2×10 cells) were injected intravenously (i.v.) standard treatments, leaving few clinical options and a approximately 30 days prior to metastasis challenge. In some metastasis assays, mice were injected i.v. with need to identify novel approaches for young patients with + + + 6 cancer. CD45.1 CD45.2 OT- I CD8 T cells (1×10 cells) 1 day prior to CD103+ cDC1 delivery. For combination treat- Osteosarcoma is the most common primary malig- ments with checkpoint inhibitors, DC-vaccinated animals nancy of bone affecting pediatric and adult patients. were injected intraperitoneally (i.p.) with PD-1 antibody Chemotherapy and surgery are standard treatments, yet (RMP1-14; 200 µg/mouse) or CTLA-4 antibody (9H10; the 5- year survival rate is <20% for osteosarcoma patients 200 µg/mouse for the first treatment, 100 µg/mouse for who present with metastases or relapse following treat- subsequent treatments) 4 days following tumor implanta- ment. Negligible improvements have occurred in osteo- 21 22 tion, with two antibody treatments per week for 3 weeks. sarcoma therapeutic options over the past 25 years. http://jitc.bmj.com/ PD-1 and CTLA-4 antibodies were purchased from BioX- Mifamurtide, a liposome-encapsulated immunotherapy Cell company (West Lebanon, New Hampshire, USA). that activates pulmonary macrophages, improved the disease-free and overall survival of patients with osteo- MoDC vaccination sarcoma lung metastases.23 By contrast, MoDC vaccines 24–26 Murine bone marrow (BM) cultures were initiated have yielded little to no clinical responsiveness, while at 0.5×106 cells/mL in RPMI 1640 complete medium checkpoint blockade with PD-1 or CTLA-4 antibodies led containing 20 ng/mL GM-CSF . Cells were collected on September 28, 2021 by guest. Protected copyright. to objective clinical response rates
Load more

Recommended publications
  • Mepact, INN-Mifamurtide
    ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT MEPACT 4 mg powder for concentrate for dispersion for infusion 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each vial contains 4 mg mifamurtide*. After reconstitution, each mL of suspension in the vial contains 0.08 mg mifamurtide. *fully synthetic analogue of a component of Mycobacterium sp. cell wall. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Powder for concentrate for dispersion for infusion White to off-white homogeneous cake or powder. 4. CLINICAL PARTICULARS 4.1 Therapeutic indications MEPACT is indicated in children, adolescents and young adults for the treatment of high-grade resectable non-metastatic osteosarcoma after macroscopically complete surgical resection. It is used in combination with post-operative multi-agent chemotherapy. Safety and efficacy have been assessed in studies of patients 2 to 30 years of age at initial diagnosis (see section 5.1). 4.2 Posology and method of administration Mifamurtide treatment should be initiated and supervised by specialist physicians experienced in the diagnosis and treatment of osteosarcoma. Posology The recommended dose of mifamurtide for all patients is 2 mg/m2 body surface area. It should be administered as adjuvant therapy following resection: twice weekly at least 3 days apart for 12 weeks, followed by once-weekly treatments for an additional 24 weeks for a total of 48 infusions in 36 weeks. Special populations Adults > 30 years None of the patients treated in the osteosarcoma studies were 65 years or older and in the phase III randomised study, only patients up to the age of 30 years were included.
    [Show full text]
  • Stems for Nonproprietary Drug Names
    USAN STEM LIST STEM DEFINITION EXAMPLES -abine (see -arabine, -citabine) -ac anti-inflammatory agents (acetic acid derivatives) bromfenac dexpemedolac -acetam (see -racetam) -adol or analgesics (mixed opiate receptor agonists/ tazadolene -adol- antagonists) spiradolene levonantradol -adox antibacterials (quinoline dioxide derivatives) carbadox -afenone antiarrhythmics (propafenone derivatives) alprafenone diprafenonex -afil PDE5 inhibitors tadalafil -aj- antiarrhythmics (ajmaline derivatives) lorajmine -aldrate antacid aluminum salts magaldrate -algron alpha1 - and alpha2 - adrenoreceptor agonists dabuzalgron -alol combined alpha and beta blockers labetalol medroxalol -amidis antimyloidotics tafamidis -amivir (see -vir) -ampa ionotropic non-NMDA glutamate receptors (AMPA and/or KA receptors) subgroup: -ampanel antagonists becampanel -ampator modulators forampator -anib angiogenesis inhibitors pegaptanib cediranib 1 subgroup: -siranib siRNA bevasiranib -andr- androgens nandrolone -anserin serotonin 5-HT2 receptor antagonists altanserin tropanserin adatanserin -antel anthelmintics (undefined group) carbantel subgroup: -quantel 2-deoxoparaherquamide A derivatives derquantel -antrone antineoplastics; anthraquinone derivatives pixantrone -apsel P-selectin antagonists torapsel -arabine antineoplastics (arabinofuranosyl derivatives) fazarabine fludarabine aril-, -aril, -aril- antiviral (arildone derivatives) pleconaril arildone fosarilate -arit antirheumatics (lobenzarit type) lobenzarit clobuzarit -arol anticoagulants (dicumarol type) dicumarol
    [Show full text]
  • WO 2013/138665 Al 19 September 2013 (19.09.2013) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization I International Bureau (10) International Publication Number (43) International Publication Date WO 2013/138665 Al 19 September 2013 (19.09.2013) P O P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every C07C 279/04 (2006.01) A61P 35/00 (2006.01) kind of national protection available): AE, AG, AL, AM, A61K 31/155 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, (21) International Application Number: DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, PCT/US2013/031733 HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, (22) International Filing Date: KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, 14 March 2013 (14.03.2013) ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, (25) Filing Language: English RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, (26) Publication Language: English TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: 61/61 1,967 16 March 2012 (16.03.2012) US (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, (71) Applicant: SANFORD-BURNHAM MEDICAL RE¬ GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, SEARCH INSTITUTE [US/US]; 10901 North Torrey UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, Pines Road, La Jaolla, CA 92037 (US).
    [Show full text]
  • Estonian Statistics on Medicines 2016 1/41
    Estonian Statistics on Medicines 2016 ATC code ATC group / Active substance (rout of admin.) Quantity sold Unit DDD Unit DDD/1000/ day A ALIMENTARY TRACT AND METABOLISM 167,8985 A01 STOMATOLOGICAL PREPARATIONS 0,0738 A01A STOMATOLOGICAL PREPARATIONS 0,0738 A01AB Antiinfectives and antiseptics for local oral treatment 0,0738 A01AB09 Miconazole (O) 7088 g 0,2 g 0,0738 A01AB12 Hexetidine (O) 1951200 ml A01AB81 Neomycin+ Benzocaine (dental) 30200 pieces A01AB82 Demeclocycline+ Triamcinolone (dental) 680 g A01AC Corticosteroids for local oral treatment A01AC81 Dexamethasone+ Thymol (dental) 3094 ml A01AD Other agents for local oral treatment A01AD80 Lidocaine+ Cetylpyridinium chloride (gingival) 227150 g A01AD81 Lidocaine+ Cetrimide (O) 30900 g A01AD82 Choline salicylate (O) 864720 pieces A01AD83 Lidocaine+ Chamomille extract (O) 370080 g A01AD90 Lidocaine+ Paraformaldehyde (dental) 405 g A02 DRUGS FOR ACID RELATED DISORDERS 47,1312 A02A ANTACIDS 1,0133 Combinations and complexes of aluminium, calcium and A02AD 1,0133 magnesium compounds A02AD81 Aluminium hydroxide+ Magnesium hydroxide (O) 811120 pieces 10 pieces 0,1689 A02AD81 Aluminium hydroxide+ Magnesium hydroxide (O) 3101974 ml 50 ml 0,1292 A02AD83 Calcium carbonate+ Magnesium carbonate (O) 3434232 pieces 10 pieces 0,7152 DRUGS FOR PEPTIC ULCER AND GASTRO- A02B 46,1179 OESOPHAGEAL REFLUX DISEASE (GORD) A02BA H2-receptor antagonists 2,3855 A02BA02 Ranitidine (O) 340327,5 g 0,3 g 2,3624 A02BA02 Ranitidine (P) 3318,25 g 0,3 g 0,0230 A02BC Proton pump inhibitors 43,7324 A02BC01 Omeprazole
    [Show full text]
  • Kosei Et Al.Pdf
    This is a repository copy of Mifamurtide for the treatment of nonmetastatic osteosarcoma. White Rose Research Online URL for this paper: http://eprints.whiterose.ac.uk/98189/ Version: Submitted Version Article: Ando, K., Mori, K., Corradini, N. et al. (2 more authors) (2011) Mifamurtide for the treatment of nonmetastatic osteosarcoma. Expert Opinion on Pharmacotherapy, 2 (12). pp. 285-292. ISSN 1465-6566 https://doi.org/10.1517/14656566.2011.543129 Reuse Unless indicated otherwise, fulltext items are protected by copyright with all rights reserved. The copyright exception in section 29 of the Copyright, Designs and Patents Act 1988 allows the making of a single copy solely for the purpose of non-commercial research or private study within the limits of fair dealing. The publisher or other rights-holder may allow further reproduction and re-use of this version - refer to the White Rose Research Online record for this item. Where records identify the publisher as the copyright holder, users can verify any specific terms of use on the publisher’s website. Takedown If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing [email protected] including the URL of the record and the reason for the withdrawal request. [email protected] https://eprints.whiterose.ac.uk/ Expert Opinion On Pharmacotherapy For Peer Review Only Please download and read the instructions before proceeding to the peer review Mifamurtide for the treatment of non-metastatic osteosarcoma Journal: Expert Opinion
    [Show full text]
  • BMJ Open Is Committed to Open Peer Review. As Part of This Commitment We Make the Peer Review History of Every Article We Publish Publicly Available
    BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available. When an article is published we post the peer reviewers’ comments and the authors’ responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to. The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript. BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (http://bmjopen.bmj.com). If you have any questions on BMJ Open’s open peer review process please email [email protected] BMJ Open Pediatric drug utilization in the Western Pacific region: Australia, Japan, South Korea, Hong Kong and Taiwan Journal: BMJ Open ManuscriptFor ID peerbmjopen-2019-032426 review only Article Type: Research Date Submitted by the 27-Jun-2019 Author: Complete List of Authors: Brauer, Ruth; University College London, Research Department of Practice and Policy, School of Pharmacy Wong, Ian; University College London, Research Department of Practice and Policy, School of Pharmacy; University of Hong Kong, Centre for Safe Medication Practice and Research, Department
    [Show full text]
  • Analysis of Biological Treatments in Patients with Multiple Sclerosis in Estonia
    TALLINN UNIVERSITY OF TECHNOLOGY School of Information Technologies Kaidi Kruuspan 163484YVEM ANALYSIS OF BIOLOGICAL TREATMENTS IN PATIENTS WITH MULTIPLE SCLEROSIS IN ESTONIA Master’s thesis Supervisor: Katrin Gross-Paju MD, PhD Tallinn 2018 TALLINNA TEHNIKAÜLIKOOL Infotehnoloogia teaduskond Kaidi Kruuspan 163484YVEM SCLEROSIS MULTIPLEX’I BIOLOOGILISE RAVI ANALÜÜS EESTIS Magistritöö Juhendaja: Katrin Gross-Paju MD, PhD Tallinn 2018 Author’s declaration of originality I hereby certify that I am the sole author of this thesis. All the used materials, references to the literature and the work of others have been referred to. This thesis has not been presented for examination anywhere else. Author: Kaidi Kruuspan 14.05.2018 3 Abstract The aim of this thesis is to develop a model to analyse usage, cost and need of biological treatments in Estonia based on biological treatment used on patients with multiple sclerosis as a model. The aim is achieved by comparing the quality and availability of data in different databases. A statistical analysis was performed by using different databases (the State Agency of Medicines, the Estonian Health Insurance Fund and hospital databases). In addition, interviews were conducted with area experts. The results of synthesis and comparison of data demonstrate that even though databases provide various data, obtaining a full and comprehensive picture of the situation is complicated due to different limitations of databases. However, the trends of usage and cost can be inferred rather clearly. This thesis is written in English and is 78 pages long, including 6 chapters, 24 figures and 7 tables. 4 Annotatsioon Sclerosis multiplex’i bioloogiline ravi analüüs Eestis Bioloogiline ravi on elusorganismi poolt toodetud või sellest saadud ainet toimeainena sisaldavad ravimid, mida toodetakse biotehnoloogilistel meetoditel.
    [Show full text]
  • Mifamurtide Therapy
    NCCP Chemotherapy Regimen Mifamurtide Therapy INDICATIONS FOR USE: Regimen Reimbursement INDICATION ICD10 Code Status Mifamurtide can be used in combination with post-operative multi-agent chemotherapy for the treatment of high-grade resectable non-metastatic C41 00100a ODMS osteosarcoma after macroscopically complete surgical resection, in children, adolescents and young adults. This treatment is an option to be discussed with the patient (or parent of a child). TREATMENT: The starting dose of the drugs detailed below may be adjusted downward by the prescribing clinician, using their independent medical judgement, to consider each patients individual clinical circumstances. The recommended dose of mifamurtide for all patients is 2 mg/m2 body surface area. It should be administered as adjuvant therapy, in combination with post-operative multi-agent chemotherapy, following resection and recovery from surgery (usually +/- 3 weeks post operatively): twice weekly at least 3 days apart for 12 weeks, followed by once-weekly treatments for an additional 24 weeks for a total of 48 infusions in 36 weeks. Treatment should continue to completion or until unacceptable toxicity occurs. Please Refer to NCCP regimen 00463 (MAP) Methotrexate (12000mg/m2) DOXOrubicin (37.5mg/m2/day) and CISplatin (60mg/m2) Therapy which is usually used in conjunction with Mifamurtide Therapy. Day Drug Dose Route Diluent & Rate Weeks 1 and 4 Mifamurtide 2mg/m2 IV infusion 50ml* 0.9% NaCl over 60 1-12 inclusive minutes 1 13-36 inclusive *The final volume will be greater than 50 ml as the required dose is added to 50 ml 0.9% NaCl giving a total volume between 50 ml - 100 ml.
    [Show full text]
  • Antigen Binding Protein and Its Use As Addressing Product for the Treatment of Cancer
    (19) TZZ 58Z9A_T (11) EP 2 589 609 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 08.05.2013 Bulletin 2013/19 C07K 16/28 (2006.01) (21) Application number: 11306416.6 (22) Date of filing: 03.11.2011 (84) Designated Contracting States: (72) Inventors: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB •Beau-Larvor, Charlotte GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO 74520 Jonzier Epagny (FR) PL PT RO RS SE SI SK SM TR • Goetsch, Liliane Designated Extension States: 74130 Ayze (FR) BA ME (74) Representative: Regimbeau (83) Declaration under Rule 32(1) EPC (expert 20, rue de Chazelles solution) 75847 Paris Cedex 17 (FR) (71) Applicant: PIERRE FABRE MEDICAMENT 92100 Boulogne-Billancourt (FR) (54) Antigen binding protein and its use as addressing product for the treatment of cancer (57) The present invention relates to an antigen bind- of Axl, being internalized into the cell. The invention also ing protein, in particular a monoclonal antibody, capable comprises the use of said antigen binding protein as an of binding specifically to the protein Axl as well as the addressing product in conjugation with other anti- cancer amino and nucleic acid sequences coding for said pro- compounds,such as toxins, radio- elements ordrugs, and tein. From one aspect, the invention relates to an antigen the use of same for the treatment of certain cancers. binding protein, or antigen binding fragments, capable of binding specifically to Axl and, by inducing internalization EP 2 589 609 A1 Printed by Jouve, 75001 PARIS (FR) EP 2 589 609 A1 Description [0001] The present invention relates to a novel antigen binding protein, in particular a monoclonal antibody, capable of binding specifically to the protein Axl as well as the amino and nucleic acid sequences coding for said protein.
    [Show full text]
  • Role of Tumor-Associated Macrophages in Sarcomas
    cancers Review Role of Tumor-Associated Macrophages in Sarcomas Tomohiro Fujiwara 1,2,* , John Healey 2, Koichi Ogura 2, Aki Yoshida 1 , Hiroya Kondo 1, Toshiaki Hata 1, Miho Kure 1 , Hiroshi Tazawa 3,4 , Eiji Nakata 1 , Toshiyuki Kunisada 1 , Toshiyoshi Fujiwara 3 and Toshifumi Ozaki 1 1 Department of Orthopaedic Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558, Japan; [email protected] (A.Y.); [email protected] (H.K.); [email protected] (T.H.); [email protected] (M.K.); [email protected] (E.N.); [email protected] (T.K.); [email protected] (T.O.) 2 Department of Surgery, Orthopaedic Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; [email protected] (J.H.); [email protected] (K.O.) 3 Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558, Japan; [email protected] (H.T.); [email protected] (T.F.) 4 Center for Innovative Clinical Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558, Japan * Correspondence: [email protected] Simple Summary: Recent studies have shown the pro-tumoral role of tumor-associated macrophages (TAMs) not only in major types of carcinomas but also in sarcomas. Several types of TAM-targeted drugs have been investigated under clinical trials, which may represent a novel therapeutic approach for bone and soft-tissue sarcomas. Citation: Fujiwara, T.; Healey, J.; Ogura, K.; Yoshida, A.; Kondo, H.; Abstract: Sarcomas are complex tissues in which sarcoma cells maintain intricate interactions with Hata, T.; Kure, M.; Tazawa, H.; their tumor microenvironment.
    [Show full text]
  • WHO Drug Information Vol
    WHO Drug Information Vol. 25, No. 1, 2011 World Health Organization WHO Drug Information Contents International Harmonization Mometasone furoate/formoterol fumarate: 14th International Conference of Drug withdrawal of marketing authorization Regulatory Authorities 1 application 37 International Conference of Drug Briakinumab: withdrawal of marketing Regulatory Authorities: personal authorization application 37 reminiscences 18 Omacetaxine mepesuccinate: withdrawal of marketing authorization application 38 Zoledronic acid: withdrawal of application WHO Prequalification of for an extension of indication 38 Medicines Programme Pandemic influenza vaccine (H5N1): Inspection of API manufacturing sites 24 withdrawal of marketing authorization application 38 Safety and Efficacy Issues ENCePP launch electronic register ATC/DDD Classification of studies 28 ATC/DDD Classification (temporary) 40 Methysergide and retroperitoneal fibrosis 28 ATC/DDD Classification (final) 43 Clozapine and life-threatening gastro- intestinal hypomotility 29 Recent Publications, Tamoxifen and anti-depressants: drug interaction 30 Information and Events Dronedarone : severe liver injury 31 Assessment of 26 African regulatory Dolasetron mesylate: abnormal heart authorities 46 rhythm 32 Quality of antimalarials in sub-Saharan Sitaxentan: update following withdrawal 32 Africa 46 Bevacizumab use in breast cancer Good governance for medicines 47 treatment 33 EC/ACP/WHO Partnership on Pharma- Latest developments in pharmaco- ceutical Policies 47 vigilance 33 Recommended International
    [Show full text]
  • NICE TECHNOLOGY APPRAISAL MEDICINES REPORT St George’S Healthcare NHS Trust Compliance Indicator Key for Medicine-Related NICE Technology Appraisals
    NICE TECHNOLOGY APPRAISAL MEDICINES REPORT St George’s Healthcare NHS Trust Compliance indicator key for medicine-related NICE Technology Appraisals A. Guidance has been approved by the Drugs and Therapeutics Committee as recommended within the NICE technology appraisal B. Guidance has been terminated C. Guidance is not relevant to the Trust as the treatment pathway is not commissioned Red: St George’s Healthcare formulary diverges from the NICE recommendations Green: Approved on National Cancer Drug Fund (CDF) list for specific indications (provided patient fulfils specific criteria) - 1 - Last Updated: October 2014 NICE TECHNOLOGY APPRAISAL MEDICINES REPORT Ref TA Title Date Guidance Formulary Compliance Issued status 3 months indicator after publication Lenalidomide is recommended as an option, within its marketing authorisation, that Lenalidomide for is for treating transfusion-dependent anaemia caused by low or intermediate-1 risk treating myelodysplastic myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic syndromes associated Sept 322 abnormality when other therapeutic options are insufficient or inadequate, with the Formulary A with an isolated 2014 deletion 5q following condition: cytogenetic The drug cost of lenalidomide (excluding any related costs) for people who abnormality remain on treatment for more than 26 cycles (each of 28 days; normally a period of 2 years) will be met by the company. Dimethyl fumarate is recommended as an option for treating adults with active relapsing-remitting multiple sclerosis (normally defined as 2 clinically significant relapses in the previous 2 years), only if: they do not have highly active or rapidly evolving severe relapsing-remitting Dimethyl fumarate for treating Aug multiple sclerosis and 320 Formulary A relapsing-remitting 2014 multiple sclerosis the manufacturer provides dimethyl fumarate with the discount agreed in the patient access scheme.
    [Show full text]